[63] A second trial, called Stalevo Reduction in Dyskinesia Evaluation (STRIDE-PD), was designed to evaluate whether Stalevo would delay the onset of dyskinesia compared with levodopa/carbidopa.

A dopa decarboxylase inhibitor (DDCI), such as carbidopa or benserazide, is administered with levodopa to attenuate its peripheral conversion to dopamine, reduce nausea and increase central ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately 1,210 thousand in the US in 2023 which is expected to increase during the ...

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy ...

Initially restoration of striatal dopamine with oral levodopa provides substantial benefit, but with long term treatment and disease progression, levodopa can elicit additional clinical symptoms, ...

Parkinson’s disease (PD) is associated with an increased risk of melanoma, but the link between levodopa therapy and melanoma is less clear. The Electronic Medicines Compendium (EMC) explicitly ...

The Clean Development Mechanism (CDM), defined in Article 12 of the Protocol, allows a country with an emission-reduction or emission-limitation commitment under the Kyoto Protocol (Annex B Party) to ...

Movement disorders are neurological conditions in which patients manifest a diverse range of movement impairments. Distinct structures within the basal ganglia of the brain, an area involved in ...

In addition, several neurological disorders tend to fluctuate in disease severity, which implicates that assessment of FMT efficacy might be difficult. The mechanism of action of FMT might be ...

The mechanism of enzyme catalysis is similar in principle to other types of chemical catalysis, for instance by involving a combination of several different types of catalysis. Determining enzyme ...

Good morning and thank you for standing by. Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any ...

Lissencephaly is a severe neurodevelopmental disease often caused by mutations in the Dcx gene. Using a human cellular model of lissencephaly, the authors report that DCX restricts neuronal ...